TRANSACTIONS
OFTHE
ROYAL
SOCIETY
OFTROPICAL
Single dose artemisinin-mefloquine
falciparum malaria
MEDICINE
AND
HYGIENE
versus mefloquine
(1997) 91,191-194
191
alone for uncomplicated
Bich Lien’, Ho Phi Long3,Tran Nhu Hun$, Nguyen
Le Ngoc Hungl, Peter J. deVries 2, LeThi DiemThuy’,
1 Tropical Diseases Clinical Research Centre, Cho Ray Hospital, Ho
Van Nam4, Trinh Kim Anhl and Ret A. Kage6
Chi Minh City, Viet Nam; 2Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, AmsterStation, Binh
dam, The Netherlands; 3Duc Linh District Hospital, Binh Thuan Province, Viet Nam; 4Provincial Malaria
Thuan Province, Viet Narn
Abstract
The efficacy of the combination of a single oral dose of 500 mg artemisinin with a single 500 mg oral dose
of mefloquine (AM) in the treatment of uncomplicated falciparum malaria was compared to mefloquine
therapy alone (M) in a double-‘blind’
randomized study in an endemic area in the south ofViet Nam
where single low dose treatment was employed and where mefloquine had been recently introduced. 231
patients, 117 AM and 114 M, were studied. Failure of therapy occurred in 1 AM patient and in 3 M patients. The radical cure rate was 84% for the AM regimen and 65% for the M regimen Ip=O.O02).
Recrudescence (including an unknown percentage of reinfections) occurred in 15% of AM patients and
in 30% of M patients (-0.01).
The mean parasite clearance time was 40 h (SD=16) for AM and 60 h
(~~=27)
for the M regimen (P=O.OOOl). No effect of artemisinin was noted on gametocytes present on
admission, but new gametocytes developed less frequently in the AM group. The addition of a single dose
of 500 mg artemisinin to 500 mg mefloquine increased the efficacy and reduced the rate of recrudescence,
but this regimen was not adequate and, for short course regimens, more doses of artemisinin as well as
higher doses of mefloquine should be studied.
Keywords:
malaria, Plasmodium falciparum, chemotherapy,
Introduction
Resistance of Plasrnodium falciparum to 4-aminoquinolines and sulfadoxine-pyrimethamine
is widespread in
Viet Nam. Quinine resistance has not been documented
unequivocally but treatment with quinine has substantial side effects and there is poor compliance with the
lengthy, therapeutic course.
New, effective therapeutic regimens which are easy to
comply with are needed. Early treatment is important to
prevent the progress of disease and to reduce mortality.
Mefloquine was available in Viet Nam to a limited extent; the price precluded its use in rural areas. Fears existed about its toxicity and side effects, especially
vomiting at higher dose, and there was very little information on its efficacy.
In a double-‘blind’
study low dose mefloquine (10
mgikg) resulted in 100% clinical cure of 80 adults and
40 children with malaria @NH et al., 1990). This dose
was as effective as a higher dose of 15-20 mg/kg in children. However, patients were followed for only 7 d, not
till day 28. Artemisinin
(qinghaosu) and derivatives
have proved to be very effective antimalarial drugs without significant side effects but monotherapy results in
recrudescences in a large proportion of patients. Longer
duration of therapy reduces this rate but is in conflict
with good compliance. Thus the combination of an artemisinin drug that gives fast initial parasite killing with
another drug that prevents recrudescence is a logical
step. This strategy may also limit the development of resistance to artemisinin and the combination drug.
The combination of artemisinin with low dose mefloquine was used to some extent in 1992 in the south of
Viet Nam. Thus we decided to study whether this combination was more effective than mefloquine alone and
to see if any of these regimens could be advocated in the
countryside, where they were already tentatively employed.
Patients and Methods
The study was carried out from February 1993 until
September 1994 at the hospital in Due Linh District,
Binh Thuan Province, in the south of Viet Nam. The
Address for correspondence: Dr Peter J. de Vries, Division of
Infectious Diseases, Tropical Medicine and AIDS, Academic
Medical Centre, P.O. Box 22700, 1100 DE Amsterdam, The
Netherlands; phone +31 20 566 4380, fax +31 20 697 2286.
artemisinin,
mefloquine,Viet
Nam
district is a so-called new economic area, with land recently made available for cultivation. This lowland area
is mainly inhabited by people who moved in from areas
non-endemic for malaria. The population in the surrounding forest mountains has some degree of immunity against malaria because of the more intense
transmission.
Patients older than 8 years with uncomplicated falciparum malaria and parasitaemia between 1000 and
1OOOOOi~L (0.025-2.5%) were included in the study if
they or their guardians gave informed consent. Complicated malaria, pregnancy, lactation, mixed infections,
inability to take oral medication, and previous participation in the study were criteria for exclusion, as were
known allergy to one of the compounds and intake of
quinine in the previous 12 h, of artemisinin or derivatives in the previous 24 h, or of mefloquine, tetracycline
or doxycycline during the last 7 d. Use of chloroquine
and sulfadoxine-pyrimethamine
were not regarded as a
reason for exclusion because of widespread resistance to
these drugs.
The study was a randomized, double-‘blind’ comparison between a regimen of 500 mg artemisinin (produced by ACF-Chemie,
Maarssen, The Netherlands,
from Vietnamese artemisinin) followed 2 h later by mefloquine (MephaquineTM; Mepha, Switzerland) (combination therapy) and a regimen of placebo followed 2 h
later by mefloquine. Mefloquine was given at 500 mg
for patients with a body weight over 37.5 kg, and 375
mg for patients of less weight.
Based on the few available data of efficacy and an expected number of 20 drop-outs per group, it was estimated that 120 patients were needed in each group
(a=0*05, p=O.S). Patients were admitted to hospital,
physical examination was performed every day and
symptoms were recorded. Vital signs were recorded
every 8 h until at least 3 normal readings of temperature
(137°C axillary) were obtained.
Fever and parasite clearance times were defined as the
time from drug administration to the first of 3 consecutive normal temperature readings and the first of 3 negative blood slides, respectively. Thick and thin blood
films were prepared every 8 h. Patients were discharged
from hospital after fever and parasite clearance, and
then blood films were prepared on an out-patient basis
7, 14, 21 and 28 d after the start of therapy. Blood films
were examined at the study site and reviewed at Cho
LE NGOC
192
Ray Hospital, Ho Chi Minh City. Parasite density was
expressed as the number of parasites per PL, estimated
from the number of parasites per leucocyte in a thick
blood film multiplied by the white blood cell count per
FL. Clinical and parasitological outcome were assessed
separately. Clinical failure was defined as no clinical improvement, necessitating additional treatment within
the first 48 h of treatment (early failure) or after 48 h of
therapy (late failure).
Parasitological response was defined as follows. Radical cure: parasite clearance by day 7 without recrudescence up to day 28; RI: disappearance of parasites with
no asexual parasite detected at day 7 but recrudescence
before day 14 (early RI) or on days 14-28 (late RI); RII:
marked reduction of the parasite count to ~25% of the
initial value, without clearance by day 7; RIII: no response or only a small decrease of parasitaemia to not
less than 25% of the initial value assessed 48 h after
therapy. In cases of clinical failure, therapy consisted of
intravenous artesunate and oral mefloquine; in cases of
recrudescence, the local standard treatment was given
(artemisinin-mefloquine
or quinine).
A symptom was regarded as a drug-related side effect
if it occurred after initiation of therapy or, if already
present before the first dose, increased in intensity
thereafter. Data were entered into the computer program Epi-Info (version 5.01 b, July 1991; Centers for
Disease Control and Prevention, Atlanta, Georgia,
USA). Student’s t test, the Kruskal-Wallis
and x2 tests
were performed with this package and with Statview@
on an Apple Mackintosh computer. Cox’s regression
analysis of the cumulative fever, parasite clearance and
recrudescence was performed with KMSURV@
(Ludwig
Institute for Cancer Research, SBo Paula, Brazil). Statistical significance was taken as PcO.05. No interim
analysis was scheduled beforehand.
All patients were informed about the study and oral
consent was obtained. The study protocol was approved
by the medical ethics committee of the Academic Medical Centre, Amsterdam, The Netherlands, and institutional clearance was obtained from Cho Ray Hospital,
Viet Nam.
Results
Two hundred and forty patients participated in the
study (122 receiving combination therapy, 118 mefloquine only). On review of the slides, 9 patients (5 combination, 4 mefloquine) appeared to have been wrongly
included because they had l? vivax infections (~2x8) or
gametocytes only (nil). Three cases who had an initial
narasite count >lOO OOO/uL and 2 children who apbeared to be 6 years old dad been wrongly entered b;t
were not excluded. The demographic characteristics of
the 23 1 included patients, some base-line values and the
dosages per kg body weight, are shown in Table 1.
Table 1. Characteristics
of 231 patients
regimens in the south ofViet Nam
No. of subjects
Sex (male/female)
Age (years)
Weight (kg)
Body temperature on admission (“C)
Initial parasitaemia (/pL)
Baseline gametocyte prevalenced
Artemisinin dose (mg/kg)
Mefloquine dose (mg/kg)
ETAL.
There was no significant difference between the groups
with respect to these quantities. The outcome is shown
in Table 2.
One combination therapy patient left the hospital before any end-point had been reached. In bo& groups
there was one earlv clinical failure. The combination
therapy failure, wh’o had an initial parasite count of
SOOOOipL, deteriorated clinically, not parasitologically,
and was given intravenous artesunate 24 h after starting
therapy. Thereafter he recovered. The mefloquine patient, who had an initial parasite count of lOOOOO/~L,
developed signs of cerebral malaria, concurrent with an
increase of the parasite count to 2OOOOO/mL. Intravenous artesunate was administered 28 h after the mefloquine dose, but the patient died in respiratory failure on
the way to a referral hospital. One patient in the mefloquine group was given artesunate at 48 h because of an
RI11 parasitological response. He quickly responded.
Another patient (also on mefloquine) developed signs of
respiratory failure at 48 h, when parasitaemia had disappeared. She was referred for supportive treatment and
recovered.
Parasitological results, parasite clearance times for the
patients who recovered without additional treatment
(excluding the RI1 cases), and fever clearance times are
shown in Table 2. The mean parasite clearance time
was 15 h (SD=7)
for patients receiving combination
therapy and 25 h (~D=18)
for recipients of mefloquine
only (l?<O-0001). The corresponding mean 95% parasite clearance times were 22 h (SD=% and 40 h ts~=25)
There was a weak positive correlation between baseline parasitaemia and parasite clearance time in both
groups (r=O.374, P=O~OOOl for combination therapy
and r=0.924. F=O.O16 for mefloauine alone). No other
association between baseline parasitaemia and outcome
was found. Cox’s regression analysis of the cumulative
proportion of parasitaemic patients showed that those
patients receiving combination therapy cleared parasites
faster than
those receiving
mefloquine
alone
(P<0~0001).
The parasite clearance time in the combination therm
spy group was similar in patients with different parasitel&ical outcomes. In the mefloquine group, the mean
uarasite clearance time was 53 h @~=25) for radicallv
cured patients, 87 h (SD=26) for iatients’with
early rel
crudescences (FYO.05 compared with radical cure) and
68 h (SD=%?)
for patients with late recrudescences
(P<O.O5 compared to radical cure and also to early rem
crudescence). The parasitological outcome and parasite
clearance time were not related to the mean dose per kg
body weight of artemisinin and/or mefloquine in either
groip. The recrudescence rate shown in Table 2 was
calculated for oatients who were followed UD to 28 d after starting &erapy (rhe differente was I significant,
I
with uncomplicated
Artemisinin
HUNG
falciparum
malaria
Treatment
plus mefloquineb
117
106111
25f8 (6-50)
47*9(16-61)
38.W 1.1(375-39.4)
27154*47226(1000-437500)
30% (35/l 16)
11.5+4.1(8.2-32.3)
10+X2.4(8.2-24.2)
aData are expressed as meatisr, (range in parentheses), except gametocyte prevalence.There
the 2 groups.
bTwo capsules of 250 mg artemisinin each plus 2 tablers of 250 mg mefloquine each.
=Two tablets of 250 mg mefioquine each.
Percentage of subjects with gametocytaemia.
treated
with two different
regimena
MefloquineC
114
97117
26f8 (6-59)
4618 (17-61)
38.9f
1.0(37.5-41.4)
24565*21267(1000-100000)
30% (341113)
Nil (placebo)
10~9+2~0(8~2-22~1)
was no significant difference between
SINGLE
DOSE ARTEMISININ-MEFLOQUINE
Table 2. Outcome
of two treatment
193
FOR MALARIA
regimens
for uncomplicated
falciparum
malaria
Regimen
Artemisinin
plus mefloquinea
No. of subjects
Not evaluable (early drop-out)
Failure
Early
Late
Lost before day 7d
Lost days 7-2Se
Resistant (RII)
Recrudescence
Early
Late
Ratef
Radical cure
Parasite clearance time h)s
Fever clearance time (h)6
Mefloquineb
Total
117
1
114
-
231
1
1
-
1
2c
1
1
3c
2
2
2
1
7
22
27
21%
171
-
15
10
15%
4o’r l&l
12)
22+ 14 (O-64)
3
3&
60i2S7(:-144)
31+27(0-120)
aTwo capsules of 250 mg artemisinin each plus 2 tablets of 250 mg mefloquine each.
tablets of 250 mg mefloquine each.
bTwo
CSeetext for details.
dLost for evaluation of radical cure or recrudescence, after initial recovery and parasite clearance.
eLost for calculation of recrudescence rate but included in logistic regression analysis.
devaluated in 114, 106 and 220 subjects, respectively.The difference between regimens was significant (PO.01, Kruskal-Wallis test).
gMean +sD (range in parentheses); evaluated in 113 and 100 subjects, respectively. The difference between regimens was significant
(P~O~0001, Kruskal-Wallis
test.
hMeanrtSD (range in parentheses; 0 indicates absence of fever on admission); evaluated in 117 and 114 subjects, respectively. The
difference between regimens was significant (P=O,OO15, Kruskal-Wallis
test).
P=O.Ol). Assuming ‘best and worst scenarios’ (classifying the drop-outs as cured, or as having recrudescences,
respectively) gave comparable results (P=O.O 1 for both).
The radical cure rate was calculated as a proportion of
all included patients: 97/116=84% for combination
therapy (excluding the single non-evaluable patient)
and 74/114=65% for mefloquine alone (PO.002). If
the denominator was calculated on an ‘intention to
treat’ basis, the absolute percentages of radical cure
were slightly smaller than when only patients who were
followed for 28 d were included. Analysis of proportional cumulative recrudescences, including patients who
were lost from follow-up between days 7 and 28, revealed a significant difference between the 2 treatment
regimens in favour of the combination
treatment
(PO.006).
Gametocytes were detected at the initial examination-i.e.,
before or during the first 24 h after the artemisininiplacebo
dose in 30% of the patients in both
groups (Table 1). No difference in the rate of disappearance of gametocytes was noted between the 2 groups.
Gametocytes were more frequently detected during the
out-patient follow-up period in patients who already
had gametocytes at the initial examination. Two of 80
combination patients and 14 of 75 receiving mefloquine
only, who had no gametocytes initially, developed
gametocytaemia at some time during follow-up (relative
risk, combination vs. mefloquine, was 0.11 [95% confidence interval 0.02-050, P=O.O03]). In the mefloquine
only group, gametocytes were significantly more often
present in patients with early recrudescences than in
radically cured patients or patients with late recrudescence. This effect was not seen in the combination
group.
Vomiting occurred in one patient during combination
treatment, and in none of those receiving mefloquine
alone. A second dose of mefloquine was tolerated well.
No other side effect was noted.
Discussion
The study showed that a low single dose of mefloquine (c. 10 mg/kg body weight) was followed by a high
rate of recrudescence (30%) and was therefore not adequate for the treatment of uncomplicated falciparum
malaria in the south of Viet Nam. The addition of a single dose of artemisinin resulted in faster disappearance
of parasites, quicker defervescence, and a lower recrudescence rate but a recrudescence rate of 15% is also
not acceptable. Reinfection and recrudescence could
not be differentiated; how great is the chance of reinfection in the area is not known, but it is presumably small.
Some of the recrudescences in both groups could have
been due to reinfection, and the performance of the
combination
treatment might therefore have been
slightly better than presented. The predominance of
male patients suggested that infection occurred outdoors. Men often worked in the forests where they
stayed overnight without the protection of bed nets.
No side effect was documented except for occasional
vomiting. The intake of the medication gave no problem
and, since this regimen can be applied while observing
the patient for a short period, the combination of artemisinin with mefloquine seems to be very suitable for outpatient treatment.
The effective dose of artemisinin has been determined
empirically. The limited pharmacokinetic data available
indicate that, after an oral dose of 500 mg, plasma concentrations are above the minimum inhibitory concentration for 12 h (DUC et al., 1994). Whether the dose in
combination with mefloquine should be the same as
that used in monotherapy is not completely clear. Clinical studies in China used higher dosages of artemisinin
and mefloquine than in the present study, but the sample sizes were small and no real dose-finding was done
@A.NG et al., 1982; LI et al., 1984).
Combinations of other artemisinin derivatives with
mefloquine have been shown to be effective in the treatment of uncomplicated falciparum malaria in Thailand
(LOOAREESUWAN
&mI3WANG
et
et al.,
1992;
BUNNAG
et al.,
1995;
al., 1995). Suitable doses of artemisinin
cannot, however, be inferred from these studies on its
derivatives.
The recommended dose of mefloquine as monotheraPY is 15 ma/kg
- - bodv weight (WHO, 1990) but in Thailand higher dosages are-needed. The optimal dose in
combination with artemisinin and derivatives has not
yet been defined. There are suggestions that, in combinations of artesunate or artemether with mefloquine,
194
LE NGOC HUNG ITAL.
plasma concentrations of mefloquine are lower than
with monotherapy (KARBWANG et al., 1994, 1995).
Clinical studies comparing the efficacv of low (15 mz/
kg) and high (25 mg&g) d&es of meflbquine in‘combynation with artemether in Thailand were not conclusive
(BUNNAG et al., 1995; KARBWANG et al., 1995). The results of the present study cannot readily be compared to
results from Thailand. In Thailand, mefloquine resistance has evolved quickly since the drug was introduced
(NOSTEN et al., 199 1; WONGSRICHANALAI et al., 1992).
The present study started at a time when artemisinin
and mefloquine were not readily available in Due Linh.
At that time, the prevalent malaria parasites could be regarded as naive with respect to exposure to the 2 drugs
and throughout the duration of the study the response
to therapy did not change.
The artemisinin-mefloquine
combination was more
effective than mefloquine alone for initial parasite killing. This is in agreement with previous studies, all showing that artemisinin and derivatives are fast acting
compounds. The difference in recrudescence rate between our 2 groups of patients showed that this rapid initial parasite killing had some protective effect against
recrudescence. The difference may be a reflection of the
chance that a parasite survives long enough to initiate a
recrudescence, a chance that is smaller when the parasite burden is eliminated more efficiently. Similarly, the
difference in the prevalence of gametocytaemia during
follow-up can be explained. No effect on the gametocytes was detected initially, but the rapid elimination of
parasites by artemisinin .decreases the chance of gametocytes developing later. A direct effect of artemisinin on
gametocytes, reported by KUMAR & ZHENG (1990) and
DUTTA et aZ. (1990), could not be confirmed in this
study.
In conclusion, a single 500 mg dose of artemisinin (10
mgikg) added to a single 500 mg dose of mefloquine (10
mgikg) is effective for initial parasite killing and reduces
the recrudescence rate in uncomplicated
falciparum
malaria, as well as gametocyte development. Longer
therapy with artemisinin and a higher dose of mefloquine will be needed to prevent recrudescence and thus
the risk of selection of resistant strains of P. falciparum.
Acknowledgements
This study was supported by the Ministry of Development
Co-operation ofThe Netherlands. The People’s Committee of
Due Linh District in Viet Nam has been unsurpassable in its
support for this study. We are grateful to Dr Vu Thi Tuyet and
technician Nguyen Phuc Tien for examining the blood films.
An Apple Mackintosh laptop computer was kindly provided by
Apple BV, The Netherlands.
Thoa, K. & Ladinsky, J. (1990). Double-blind
studies with
mefloquine alone and in combination with sulfadoxine-pyrimethamine in 120 adults and 120 children with falciparum
malaria inViet Nam. Transactions of the Royal Society ofTropical Medicine and Hwiene. 84, 50-53.
Bunnag, D., Kanda, y, Karbwang, J., Thimasarn, K., Pungpak, S. & Harinasuta, T. (1995). Artemether-mefloquine
combination
in multidrug resistant falciparum malaria.
Transactions of the Royal Society of Tropical Medicine and Hy&ne. 89. 213-215.
Die, D’. D:, DeVries, P. J., Khahn, N. X., Binh, L. N., Kager,
I? A. &Van Boxtel, C. 1. (1994). The nharmacokinetics of a
single dose of artemi&&
in healthy-Vietnamese
subjects.
American Journal of Tropical Medicine and Hygiene, 51,
7855790.
Dutta, G. I’., Mohan, A. & Tripathi, R. (1990). Study of the
gametocytocidalisporontocidal
action of qinghaosu (artemisinin) by electron microscopy. Journal of Parasitology, 76,
849-852.
Jiang, J.-B., Li, G.-Q., Guo, X.-B., Kong, Y. C. & Arnold, K.
(1982). Antimalarial activity of mefloquine and qinghaosu.
Lancet, ii, 285-288.
Karbwang, J., Na Bangchang, K.,Tahanavibul, A., Back, D. J.,
Bunnag, D. & Harinasuta, T. (1994). Pharmacokinetics of
mefloquine alone or in combination with artesunate. Bulletin
of the World Health Organization, 72, 83-87.
Kaibwang, J., Na-Bangchang, K.;Th&avibu!,
A., Ditta-in, M.
& Harinasuta, T. (1995). A comparative clmical trial of two
different regimens of artemether plus mefloquine in multidrug resistant falciparum malaria. Transactions of the Royal
Societv ofTroaica1 Medicine and Hveiene. 89.296-298.
Kumar,-NY & iheng, H. (1990). Stage-sp&c
gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmedium falciparum. Parasitology Research, ?6,-2 14-2 18.
Li, G., Arnold, K., Guo, X., Jian, H. & Fu, L. (1984). Randomised comparative study of mefloquine, qinghaosu, and
pyrimethamine-sulfadoxine
in patients with falciparum malaria. Lancet. ii. 1360-1361.
Looareesuwan; g., Kyle, D. E., Viravan, C., Vanijanonta, S.,
Wilairatana, I’., Charoenlarp, l?, Canfield, C. J. &Webster,
H. L. (1992). Treatment of patients with recrudescent falciparum malaria with a sequential combination of artesunate
and mefloquine. American Journal of Tropical Medicine and
Hygiene, 47, 794-799.
No&&, F., Ter Kuile, F., Chongsuphajaisiddhi,
T., Luxemburger, C., Webster, H. K., Edstein, M., Phaipun, L., Thew,
K. L. & White, N. J. (1991). Mefloquine-resistant
falciparum malaria on the Thai-Burmese
border. Lancet, 337,
1140-1143.
WHO (1990). Practical Chemotherapy of Malaria. Geneva:
World Health Organization, Technical Report Series, no.
805, pp. 30-31.
Wongsrichanalai, C., Webster, H. K., Womonwattrawatee, T.,
Sookto, I?, Chuanak, N., Thimasarn, K. & Wernsdorfer, W.
H. (1992). Emergence of multidrug-resistant
Plasmodium
falciparum in Thailand: in vitro tracking. American Journal of
Tropical Medicine and Hygiene, 41, 112-l 16.
References
Anh, T. K., Kim, N. V., Arnold,
Received 1.5 April 1996; revised 5 September 1996; accepted
for publication 2 October 1996
K., Chien, V. V., Bich, N. N.,